Coordinating the balance between haematopoietic stem cell (HSC) quiescence and self-renewal is crucial for maintaining haematopoiesis lifelong. Equally important for haematopoietic function is modulating HSC localization within the bone marrow niches, as maintenance of HSC function is tightly controlled by a complex network of intrinsic molecular mechanisms and extrinsic signalling interactions with their surrounding microenvironment 1 . In this study we demonstrate that nuclear factor erythroid 2-related factor 2 (Nfe2l2, or Nrf2), well established as a global regulator of the oxidative stress response, plays a regulatory role in several aspects of HSC homeostasis. Nrf2 deficiency results in an expansion of the haematopoietic stem and progenitor cell compartment due to cell-intrinsic hyperproliferation, which was accomplished at the expense of HSC quiescence and self-renewal. We further show that Nrf2 modulates both migration and retention of HSCs in their niche. Moreover, we identify a previously unrecognized link between Nrf2 and CXCR4, contributing, at least partially, to the maintenance of HSC function.
HSC quiescence and decline in the capacity for self-renewal in mouse models [10] [11] [12] . Taken together, these findings indicate that modulation of the redox balance plays a pivotal role in maintaining HSC functions.
Nrf2 belongs to the cap-n-collar subfamily of the basic leucine zipper (b-Zip) transcription factors 13 , and is ubiquitously expressed as a master regulator in the antioxidant response pathway [14] [15] [16] [17] . Although Nrf2 was found to be dispensable for murine development, growth and erythropoiesis 18 , given the continual requirement for HSC protection from oxidative stress and recent findings that Nrf2 maintains homeostatic quiescence of intestinal stem cells in Drosophila 19 , we sought to assess the role of Nrf2 in regulating HSC functions.
To determine whether Nrf2 plays a role in haematopoiesis, we first quantified the primitive HSPCs in Nrf2 −/− mice in steady-state conditions. In young adult Nrf2-deficient animals, we observed an increase in both the percentage and absolute number of LSK (Lineage − Sca-1 + c-Kit + ) cells when compared with age-matched Nrf2 +/+ wild-type (WT) controls (Fig. 1a,b) , although overall bone marrow cellularity was unchanged (data not shown). More comprehensive analysis of the LSK fraction revealed significant increases at the short-term HSC (ST-HSC, CD34 + Flt3 − ) and continued through multipotent progenitor (MPP, CD34 + Flt3 + ) stages, but did not impact on long-term HSCs (LT-HSC, CD150
+ CD48 − CD34 − Flt3 − ; Fig. 1c ). We also found increases in the number of committed downstream progenitors of both the myeloid and lymphoid lineages (Fig. 1d,e) . Consistent with these findings, we also observed significantly increased colony formation from Nrf2 −/− bone marrow in cobblestone area-forming cell (CAFC) and colony-forming cell (CFC) assays (Fig. 1f,g ). Together, these results suggest that loss of functional Nrf2 leads to expansion of the haematopoietic progenitor pool but spares the most primitive LT-HSCs.
To examine the impact of Nrf2 on HSPC function, we co-cultured sorted LSK cells from bone marrow in myeloid (CFU-GM), erythroid (BFU-E) and mixed (CFU-Mix) lineages in CFC assays; data represent mean ± s.e.m. from 13 WT and 12 Nrf2 −/− mice over 3 independent experiments. * P < 0.05; * * P < 0.01; and * * * P < 0.005. marrow in a competitive setting on OP9-DL1, which allows the in vitro analysis of T-cell development from HSPCs. As expected given their increased number in vivo (Fig. 1) , even when seeded in equal numbers, Nrf2 −/− LSKs dominated the culture as early as day 3 ( Fig. 2a and Supplementary Fig. S1a ), indicating a competitive advantage in proliferation as a result of Nrf2 deficiency. T-cell development progresses through a series of distinct stages that can be identified on the basis of their differential expression of CD4, CD8, CD25 and CD44 (ref. 20) . In addition to their enhanced proliferation, we also observed that Nrf2 −/− LSKs had enhanced differentiation kinetics when compared with WT controls (Fig. 2b and Supplementary Fig. S1b ), rapidly progressing to the DN2 (CD4 − CD8 − CD44 + CD25 + ) and DN3 (CD4 − CD8 − CD44 − CD25 + ) stages. Moreover, we found a significantly increased level of Ki-67 expression on LSKs from Nrf2 −/− when compared with WT bone marrow in vivo (Fig. 2c ), in concordance with the enhanced proliferation observed in vitro.
Given the ubiquitous expression of Nrf2, it is essential to clarify whether these differences in HSPC proliferation and differentiation kinetics are caused extrinsically by the bone marrow niche or intrinsically by the HSPC itself. To assess the role of the bone marrow niche, we generated chimaeras using CD45.1 + WT LSKs transferred into either CD45.2 + WT or CD45.2 + Nrf2 −/− hosts. After 8 weeks, which allowed for effective primary reconstitution, we sorted LSKs from these chimaeric mice and co-cultured them with OP9-DL1 stromal cells. Transplanted CD45.1 + WT LSKs behaved in a similar manner irrespective of their pre-conditioning microenvironment (Fig. 2d,e and Supplementary Fig. S1c,d) . In contrast, when we performed the reciprocal chimaeric experiment where CD45.2 + WT or CD45.
LSKs, previously primed in CD45.1 + WT hosts, were co-cultured on OP9-DL1 stromal cells, we discovered once again that transplanted CD45.2 + Nrf2 −/− LSKs proliferated more and differentiated faster than transplanted Nrf2 +/+ WT LSKs (Fig. 2f,g and Supplementary Fig. S1e ,f). Taken together, these results suggest that Nrf2 regulates proliferation and differentiation of HSPCs in a cell-intrinsic manner.
Nrf2 could be found at the transcript level in both LT-HSCs as well as their downstream MPPs ( Supplementary Fig. S1g ), suggesting that −/− donor cells in the primary transplant group and 9 recipients of WT and 10 recipients of Nrf2 −/− donor cells in the secondary transplant group over 2 independent experiments. * P < 0.05; * * P < 0.01; and * * * P < 0.005.
despite their unaltered frequency in deficient animals ( Fig. 1c ), Nrf2 could act on this earliest haematopoietic population. Consistent with our findings on the bulk LSK cells, we found that a greater proportion of Nrf2 −/− LT-HSCs expressed Ki-67 ( Fig. 2h ), indicating that more HSCs were undergoing proliferation. Functionally, Nrf2-deficient LT-HSCs differentiated more rapidly on OP9-DL1 culture than WT controls ( Fig. 2i and Supplementary Fig. S1h ). These data demonstrate that Nrf2 plays an important role in HSPC proliferation and differentiation starting at the LT-HSC stage.
On the basis of these findings, we reasoned that Nrf2 functions as a negative regulator of cell-cycle entry in HSCs, actively maintaining the balance between HSC quiescence and self-renewal. As the synthesis of cyclin D is initiated during G1 phase, and its presence is required for the transition to S phase, we first assessed the level of cyclin D expression as an indirect measure of quiescence in the bone marrow. We found a twofold increase in the number of cyclin D1
+ cells in the Nrf2 −/− bone marrow (Fig. 3a,b) , and higher levels of cyclin D at the transcript level in purified Nrf2 −/− LSKs (Fig. 3c) . Furthermore, by analysing RNA and DNA contents using Pyronin Y and Hoeschst 33342, we found fewer LSKs from Nrf2 −/− bone marrow in the quiescent G0 state (Fig. 3d) , and importantly also a reduced proportion of the most primitive LT-HSCs in the G0 stage (Fig. 3e) . These findings support our hypothesis that Nrf2 acts as a negative regulator of cell-cycle progression, thereby maintaining HSC quiescence. To further explore this phenomenon in vivo, we exploited the characteristic of 5-Fluorouracil (5-FU), which kills cycling cells and spares quiescent stem cells. Following a single dose of 5-FU, we observed a profound reduction in the number of LT-HSCs in Nrf2
−/− mice when compared with WT controls (Fig. 3f) . These findings suggest that the HSC compartment of Nrf2-deficient mice is considerably less quiescent than WT controls. Given the hyperproliferation of Nrf2 −/− HSCs, coupled with the reduction of HSC quiescence, continued insult should lead to accelerated haematopoietic exhaustion. Consistent with our hypothesis, Nrf2
−/− mice challenged with sequential 5-FU treatment died significantly earlier than WT controls (Fig. 3g) . To directly assess whether Nrf2 controls the self-renewal ability of HSCs, in addition to maintaining HSPC quiescence, we performed sequential CAFC assays in vitro and serial competitive transplantation in vivo. In both the secondary plating and transplantation, we saw a marked reduction in the contribution of Nrf2 −/− HSCs (Fig. 3h,i) . Taken together, our data demonstrate that Nrf2 plays an important role in maintaining the balance between HSC quiescence and self-renewal.
Surprisingly, despite their hyperproliferative potential in vitro, Nrf2 −/− LSKs did not possess a competitive advantage in vivo in primary recipients (Fig. 3i) , suggesting a potential role for Nrf2 in the homing and retention of HSPCs in the bone marrow niche. Interestingly, in the steady-state, Nrf2 −/− mice exhibited a significantly higher frequency and absolute number of HSPCs in the spleen (Fig. 4a) . Consistent with this finding, Nrf2 −/− splenocytes gave rise to significantly more CFU-GM and BFU-E colonies in CFC assays, and −/− LSK cells that migrated towards unconditioned media supplemented with CXCL12 at 6 h of assays; mean ± s.e.m. of 5 independent experiments. Bracketed lines in histograms represent cells expressing the marker. * P < 0.05 and * * P < 0.01.
sorted Nrf2
−/− splenic LSKs mimicked their bone marrow counterparts and once again differentiated more rapidly when co-cultured with OP9-DL1 stromal cells (Fig. 4b,c) . To address whether this increase in peripheral LSKs was due to a cell-intrinsic defect in HSPC retention, we generated chimaeras with sorted CD45.2 + WT or Nrf2 −/− LSKs transplanted into CD45.1 + WT hosts. At 8 weeks following transplant, we found significantly fewer Nrf2 −/− LSKs in the bone marrow and markedly more in the periphery (Fig. 4d-g ). To explore the homing capacity, we labelled purified Lineage-depleted (Lin − ) bone marrow cells from CD45.1 + WT and CD45.2 + WT or Nrf2 −/− mice with fluorescent dyes, injected them into lethally irradiated WT recipients, and quantified the contribution of cells present in the recipient bone marrow 18 h after transplant by flow cytometry. We observed that Nrf2 −/− Lin − bone marrow cells trafficked to the bone marrow niche less efficiently than CD45.2 + WT controls (Fig. 4h,i) , implying that Nrf2 is required for efficient homing of bone marrow cells. To specifically examine the impact of Nrf2 on the homing of HSCs, we labelled and mixed WT and Nrf2 −/− bone marrow at a 1:1 ratio, and compared the engraftment efficiency of the LT-HSCs 16 h after transplant. Although present at equal numbers in the inoculum, Nrf2 −/− LT-HSCs showed a significant impairment in bone marrow engraftment, indicating a defect in their homing ability (Fig. 4j,k) . Collectively, these findings suggest that Nrf2 governs the retention of HSCs and their homing to the bone marrow niche.
In addition to its well-described role as a crucial chemokine receptor for HSPC homing and retention, there has been considerable interest recently in CXCR4 signalling for its role in maintaining HSC quiescence [21] [22] [23] . Strikingly, our findings on the role of Nrf2 on HSC homing and quiescence closely mirrored the observations in Cxcr4 −/− adult animals. This directed us to investigate the interaction between Nrf2 and CXCR4. Although there was no change in the expression of VCAM-1 ( Supplementary Fig. S2 ), another key molecule for HSPC homing, we found a twofold reduction in the level of CXCR4 expression in Nrf2 −/− LSKs when compared with WT controls (Fig. 5a,b) , which again was observed as early as in LT-HSC stage (Fig. 5c,d ). This finding was functionally confirmed by performing in vitro Transwell migration assays, where we found that Nrf2 −/− LSKs migrated less efficiently towards CXCL12 at 6 h (Fig. 5e) , consistent with the reduced expression level of CXCR4 caused by Nrf2 deficiency in HSPCs.
To determine whether CXCR4 is a direct target of Nrf2, we scrutinized the promoter region of the mouse and human CXCR4 gene, and identified two putative conserved Nrf2-binding sites in the Cxcr4 promoter (Fig. 5f) . We cloned the Cxcr4 promoter from mouse genomic DNA into a dual luciferase reporter vector, and demonstrated that exogenous Nrf2 transactivated the minimal promoter region in vitro (Fig. 5g) . In addition, to assess whether endogenous Nrf2 binds to the Cxcr4 promoter in bone marrow, we conducted chromatin immunoprecipitation (ChIP) assays. We noted enrichment of both putative binding sites immunoprecipitated by Nrf2, confirming the physical interaction of endogenous Nrf2 and the Cxcr4 promoter in vivo (Fig. 5h) . Thus, Nrf2 directly binds to the Cxcr4 promoter and activates its expression.
Finally, we examined whether dysregulation of CXCR4 expression contributed to the dual quiescence and migration defects observed in Nrf2 −/− HSPCs. Lentiviral overexpression of CXCR4 in Nrf2 −/− LSK cells rescued the phenotype of Nrf2 −/− HSPCs in their differentiation kinetics on OP9-DL1 co-culture to a comparable pace with WT LSKs, as well as restored the homing ability of Nrf2 −/− HSPCs in Transwell migration assays (Fig. 5i-k and Supplementary Fig. S3 ). Taken together, these results suggest that Nrf2 controls multiple aspects of haematopoiesis at least partially through regulation of CXCR4 signalling.
Although Nrf2 has previously been reported to be dispensable for erythropoiesis and megakaryocyte differentiation 18, 24, 25 , here we saw that it has a critical role in maintaining HSC function through its impacts on quiescence and self-renewal and, by extension, differentiation. Consistent with previous observations, we found that Nrf2 did not seem to control lineage specification, as Nrf2 −/− HSPCs exhibited typical myeloid and lymphoid commitment. Rather, our data argue that Nrf2 functions as a master regulator of the main modalities of HSC function. Not only do we show that Nrf2 can regulate the balance between quiescence and proliferation, but also between self-renewal and differentiation, as well as homing and retention of HSCs in the bone marrow niche. This firmly establishes an important role for Nrf2 in the most primitive haematopoietic compartment. Moreover, our studies suggest that Nrf2 exerts its influence, at least in part, through direct regulation of CXCR4 expression. Importantly, previous studies have shown that among the cell-cycle regulators investigated, cyclin D1 was singularly upregulated in Cxcr4 −/− LSKs (ref. 23) , consistent with our findings that cyclin D1 was upregulated in Nrf2 −/− HSPCs. There is increasing evidence that maintaining the amount of intracellular ROS at its basal level is necessary for HSC quiescence [9] [10] [11] 26, 27 . The most widely studied transcription factors linking the ROS pathway to HSC quiescence and self-renewal are the FOXO (Forkhead O) proteins, which are important downstream effectors of the insulin/IGF-1-like signalling (ISS) pathway. Intriguingly, recent studies suggest that ISS not only inhibits DAF-16, the Caenorhabditis elegans homologue of FOXO, but also directly suppresses SKN-1, the C. elegans homologue of Nrf2, in ageing 28 . There is also mounting evidence that the ISS and ROS signalling pathways crosstalk in the regulation of ageing 29 . Interestingly, groups studying FOXO-deficient HSCs have found a similar phenotype to the one we describe here, alluding to the possibility that Nrf2 functions in parallel to the FOXO proteins as a downstream target of the PI(3)K-Akt pathway. Future research to validate the involvement of Nrf2 in the ISS pathway in mammalian models could be of considerable interest in understanding HSC ageing 30 . Finally, a recent study has demonstrated a similar negative regulatory role for Nrf2 in intestinal stem cell proliferation 19 . Considering that Nrf2 is ubiquitously expressed, and stem cells and their progenitors are critical to the maintenance and function of various tissues, these findings indicate that Nrf2 serves as a master regulator of stem cell integrity and longevity in adult tissues. Future research into understanding and manipulating Nrf2 in tissue-specific stem cells and their niches may provide insights and innovative approaches to the field of regenerative medicine.
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METHODS
Mice. Nrf2 −/− mice were a kind gift from J. Chan (University of California, Irvine, USA), and were backcrossed to the C57BL/6 background for 7-8 generations. WT (Nrf2 +/+ ) C57BL/6 (CD45.2) or B6.SJL-Ptprc a Pepc b /BoyJ (CD45.1) mice were purchased from the Jackson Laboratory. All mice were age-matched, female Nrf2 +/+ and Nrf2 −/− mice (8-12 weeks old). All mice were maintained in the MSKCC Animal Facility in Thorensten units with filtered germ-free air. Experiments were conducted in compliance with institutional guidelines at MSKCC.
Cell isolation. Bone marrow cells were flushed from intact femurs and tibia, and spleens were mashed with glass slides to generate single-cell suspension. Collection of the cells was performed in RPMI media with 10% FBS or PBS with 0.5% BSA, and filtered through a 70-µm strainer. Unless otherwise stated, all cell numbers in this study were standardized as total counts per leg or per spleen. Cell culture. Co-culture of HSPCs and OP9-DL1 stromal cell lines was previously described 31 . Briefly, isolated LSK cells were seeded on a 60-80% confluent monolayer of OP9-DL1 cells into six-well tissue culture plates in α-MEM, supplemented with 20% FBS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin, 5 ng ml −1 rmIL-7 (Miltenyi Biotec) and 5 ng ml −1 of rmFlt3L (Miltenyi Biotec). Cells were maintained at 37 • C in a humidified atmosphere containing 5% CO 2 , and were collected at the indicated intervals.
Bone marrow transplant. In the serial transplantation assay, we purified bone marrow LSK cells from CD45.2 + (WT or Nrf2 −/− ) donors and CD45.1 + (WT) competitors, mixed them at a 1:1 ratio, and transplanted 2 × 10 3 cells into lethally irradiated CD45.1 + (WT) mice (1,100 cGy total body irradiation, split dose) through tail vein injection. After 4 months of reconstitution, we assessed chimaerism of donor-derived LSK cells (CD45.2 + ) in the recipient bone marrow, as well as sort purified these cells, mixed them with new CD45.1 + (WT) competitors at a 1:1 ratio, and transplanted them into a second set of lethally irradiated CD45.1 + (WT) mice. Chimaerism in the bone marrow was again assessed 4 months after secondary transplant. In the chimaeric repopulation study, we isolated LSK cells from donor bone marrow and transplanted 2 × 10 3 cells into lethally irradiated mice, and analysed reconstitution in bone marrow after 8 weeks. In the in vivo homing assays, we isolated Lin − bone marrow cells from CD45. Immunohistochemistry. Fresh tibiae were collected and fixed in 10% formalin at room temperature overnight, decalcified for 24 h using Decalcifier I (Surgipath), washed with water and embedded in wax. Paraffin sections of 5 µm thickness were prepared using a microtome (Leica Microsystems). The sections were dewaxed in xylene, hydrated in graded alcohols, blocked in 1% hydrogen peroxide, and treated in pH 6.0 10 mM citrate buffer. The sections were then incubated with primary antibody Cyclin D1 (Thermo Scientific) overnight, followed by appropriate secondary antibodies and avidin-biotin complexes (Vector Laboratories). Antibody reaction was visualized with 3-3 diaminobenzidine (SigmaAldrich) and counterstained with haematoxylin. Tissue sections were dehydrated in graded alcohols, cleared in xylene and mounted.
5-FU treatment. 5-FU (InvivoGen) was administered to mice intraperitoneally at a dose of 150 mg kg −1 either as a single dose or once every 7 days consecutively for 3 times. Bone marrow cellularity was examined at day 3.5 in the former experiment, and the survival of individual mice was monitored daily in the latter.
Transwell cell migration assay. Purified LSK cells were incubated in IMDM media containing 20% FBS, 20 ng ml −1 murine IL-3 (PeproTech), 20 ng ml −1 SCF (PeproTech) and 20 ng ml −1 Flt3L (Amgen) at 37 • C in a humidified atmosphere containing 5% CO 2 for 18 h. LSK cells were then washed with IMEM media twice, resuspended in QBSF media (Quality Biologicals) in 0.1×10 6 ml −1 . Cell suspension (100 µl) was loaded to the upper chamber of the Transwell plate, and 600 µl of QBSF media with or without CXCL12 (200 ng ml −1 , R&D systems) was added to the lower chamber of the Transwell plate (pore size 5 µm, Corning). Cells were allowed to migrate across the membrane at 37 • C, and their migration efficiency was assessed at 6 h.
Luciferase reporter assay. CXCR4 promoter regions were identified within 2 kilobases (kb) upstream from the transcription start site of the mouse CXCR4 sequence (Genebank accession number NC_000067) as previously described 32 . Putative Nrf2-binding sites were predicted using PROMO (http://www.lsi.upc.es/ ∼ alggen). The 500-base-pair (bp) region upstream of the transcription start site of mouse CXCR4 was amplified by PCR from WT C57BL/6 mouse genomic DNA and subsequently subcloned into the pGL4.23 luciferase reporter vector (Promega), and named pCXCR4. The pCXCR4 construct was co-transfected into HEK293T cells using lipid-based 293T TransIT Reagent (Mirus Bio) with either pUC19 empty vector or Nrf2-pCMV vector, as well as phRL-TK vector as an internal control. Cells were collected 24 h after transfection and both luciferase activities were determined using the Dual-Luciferase Reporter Assay System (Promega) as per the manufacturer's instructions. 
